Breakthrough designation AstraZeneca’s severe asthma drugThe first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after Share XBreakthrough designation AstraZeneca’s severe asthma drughttps://pharmaphorum.com/news/astrazeneca-asthma-breakthrough/
GSK cuts 650 jobs in the USGlaxoSmithKline moves ahead with its planed cost saving strategy and cuts 650 jobs in North Carolina, according to Share XGSK cuts 650 jobs in the UShttps://pharmaphorum.com/news/glaxosmithkline-cuts-650-jobs/
Novartis sells parts of Sandoz for $1bnAfter disappointing sales, Novartis trades in the Sandoz US dermatology business and generic oral solids portfolio to Aurobindo Share XNovartis sells parts of Sandoz for $1bnhttps://pharmaphorum.com/news/novartis-sells-sandoz-parts/
Pfizer axes development of Duchenne muscular dystrophy antibodyPfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy Share XPfizer axes development of Duchenne muscular dystrophy antibodyhttps://pharmaphorum.com/news/duchenne-trials-axed-pfizer-dmd/
AstraZeneca improves diabetes pen to maintain its market shareThe European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug Share XAstraZeneca improves diabetes pen to maintain its market sharehttps://pharmaphorum.com/news/astrazeneca-improves-diabetes-pen-to-maintain-its-market-share/
AbbVie braces for impact of Humira biosimilars in EuropeAbbVie looks set to lose several billion dollars in revenue from Humira, as its soon to expire European Share XAbbVie braces for impact of Humira biosimilars in Europehttps://pharmaphorum.com/news/abbvie-braces-for-impact-of-humira-biosimilars-in-europe/
Pfizer drug reduces mortality in patients with fatal heart diseasePfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase Share XPfizer drug reduces mortality in patients with fatal heart diseasehttps://pharmaphorum.com/news/tafamidis-reduces-mortality/
Diggelmann leaves Roche’s diagnostics divisionRoche has been hit with another exec departure after it said Roland Diggelmann will leave his role as Share XDiggelmann leaves Roche’s diagnostics divisionhttps://pharmaphorum.com/news/diggelmann-leaves-roche/
Novartis succeeds where Roche failed with PI3K breast cancer drugNovartis published trial results showing its drug succeeded in tackling difficult to treat breast cancer with PIK3CA mutation, Share XNovartis succeeds where Roche failed with PI3K breast cancer drughttps://pharmaphorum.com/news/novartis-success-breast-cancer-inhibitor/
